Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

438 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment of 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia.
Robak T, Błasinka-Morawiec M, Krykowski E, Kasznicki M, Płuzanska A, Potemski P, Hellmann A, Zaucha JM, Lewandowski K, Dmoszynska A, Hansz J, Komarnicki M, Konopka L, Durzynski T, Ceglarek B, Sikorska A, Kotlarek-Haus S, Mazur G, Urasinski I, Zdziarska B, Maj S, Kopec I, Skotnicki AB, Dwilewicz-Trojaczek J, Grieb P, et al. Robak T, et al. Among authors: mazur g. Leuk Lymphoma. 1996 Aug;22(5-6):509-14. doi: 10.3109/10428199609054790. Leuk Lymphoma. 1996. PMID: 8882965 Clinical Trial.
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group.
Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Goździk J, Hołowiecki J, Stella-Hołowiecka B, Kachel Ł, Knopińska-Posłuszny W, Nagler A, Meder J, Walewski J, Lampka E, Sułek K, Sawicki W, Lange A, Forgacz K, Suchnicki K, Pacuszko T, Skotnicki A, Mensah P, Jurczak W, Kuliczkowski K, Wróbel T, Mazur G, Dmoszyńska A, Wach M, Robak T, Warzocha K. Czyz J, et al. Among authors: mazur g. Bone Marrow Transplant. 2002 Jul;30(1):29-34. doi: 10.1038/sj.bmt.1703590. Bone Marrow Transplant. 2002. PMID: 12105774
The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
Wrzesien-Kus A, Robak T, Jamroziak K, Wierzbowska A, Dmoszynska A, Adamczyk-Cioch M, Kuliczkowski K, Mazur G, Holowiecki J, Konopka L, Maj S, Marianska B, Zawilska K; Polish Acute Leukemia Group (PALG) phase II study. Wrzesien-Kus A, et al. Among authors: mazur g. Neoplasma. 2002;49(6):405-11. Neoplasma. 2002. PMID: 12584589 Clinical Trial.
Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience.
Robak T, Szmigielska-Kapłon A, Wrzesień-Kuś A, Wierzbowska A, Skotnicki AB, Piatkowska-Jakubas B, Kuliczkowski K, Mazur G, Zduńczyk A, Stella-Hołowiecka B, Hołowiecki J, Dwilewicz-Trojaczek J, Madry K, Dmoszyńska A, Cioch M. Robak T, et al. Among authors: mazur g. Ann Hematol. 2004 Apr;83(4):225-31. doi: 10.1007/s00277-003-0808-9. Epub 2003 Nov 26. Ann Hematol. 2004. PMID: 14648030
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A, Robak T, Wierzbowska A, Lech-Marańda E, Pluta A, Wawrzyniak E, Krawczyńska A, Kuliczkowski K, Mazur G, Kiebiński M, Dmoszyńska A, Wach M, Hellmann A, Baran W, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S; Polish Adult Leukemia Group. Wrzesień-Kuś A, et al. Among authors: mazur g. Ann Hematol. 2005 Sep;84(9):557-64. doi: 10.1007/s00277-005-1046-0. Epub 2005 Apr 27. Ann Hematol. 2005. PMID: 15856358 Clinical Trial.
Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A, Robak T, Pluta A, Zwolińska M, Wawrzyniak E, Wierzbowska A, Skotnicki A, Jakubas B, Hołowiecki J, Nowak K, Kuliczkowski K, Mazur G, Haus O, Dmoszyńska A, Adamczyk-Cioch M, Jedrzejczak WW, Paluszewska M, Konopka L, Pałynyczko G. Wrzesień-Kuś A, et al. Among authors: mazur g. Ann Hematol. 2006 Jun;85(6):366-73. doi: 10.1007/s00277-006-0099-z. Epub 2006 Mar 8. Ann Hematol. 2006. PMID: 16523310
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.
Österborg A, Udvardy M, Zaritskey A, Andersson PO, Grosicki S, Mazur G, Kaplan P, Steurer M, Schuh A, Montillo M, Kryachok I, Middeke JM, Kulyaba Y, Rekhtman G, Gorczyca M, Daly S, Chang CN, Lisby S, Gupta I. Österborg A, et al. Among authors: mazur g. Leuk Lymphoma. 2016 Sep;57(9):2037-46. doi: 10.3109/10428194.2015.1122783. Epub 2016 Jan 19. Leuk Lymphoma. 2016. PMID: 26784000 Clinical Trial.
438 results